Deal Watch: Ireland's Amryt Acquires Aegerion
Executive Summary
European firms Amryt and Evotec have signed agreements to acquire two companies based across the Atlantic – Aegerion and Just Biotherapeutics, respectively.
You may also be interested in...
AbbVie Pays $60m To Option Alpine’s Lupus Candidate
Deal Snapshot: Set to begin a Phase II study that Alpine will complete, ALPN-101 is a dual inhibitor of CD28 and ICOS that may offer a new treatment option in SLE.
Evotec Sets Empire Building Sights On Infectious Disease Space
As others shun anti-infectives, Evotec is consolidating its position. Through an alliance with Sanofi it is evaluating new anti-infectives in three areas, and expects soon to advance its first candidate therapeutic into the clinic.
Deal Watch: Merger Addresses Problems Of Both Aegerion, QLT
Convinced on safety, Shire buys Phase III-ready IBD candidate from Pfizer. Teva looks ahead to its acquisition of Allergan's generic portfolios by divesting ANDAs through two deals, while ending a stem cell collaboration with Mesoblast.